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Abstract 
Introduction:  Glioblastoma multiforme (GBM) is one of the deadliest forms of 
brain cancer, and affects more than 18,000 new cases each year in the United 
States alone.  The current standard of treatment for GBM includes surgical 
removal of the tumor, along with radiation and chemotherapy.  Despite these 
treatments, recurrence of GBM is extremely common, and once it recurs, the life 
expectancy is measured in weeks or months.  One of the reasons for the deadly 
nature of the recurrent GBM is thought to be selection for therapy-resistant tumor 
cells.  In this project, we sought to characterize the molecular changes in recurrent 
GBM specimens compared to primary GBM specimens from the same subjects.   
Methods: Whole-genome DNA microarrays were used to identify genes changed 
in mRNA expression in seven recurrent GBM samples compared to seven 
primary GBM samples from the same subjects.  Real-time quantitative RT-PCR 
was used in an attempt to validate changes seen by microarray for 18 genes of 
interest chosen from the microarray screen. 
Results:  The microarray experiments identified several dozen mRNA transcripts 
with evidence of significant differences in expression.  From these genes, we 
chose 18 for PCR validation.  Overall, the PCR experiments validated the 
microarray findings quite well.  There was a very high correlation for the 
magnitude of expression changes seen for the 18 genes (Pearson’s R = 0.852, P < 
0.001).  Individually, 13 of the 18 genes showed statistically significant changes 
by PCR in the recurrent versus primary tumor pairs.  Of the 5 genes that did not 
  
 
 
validate at the P<0.05 level, 4 showed trends in the direction predicted by the 
microarray, while 1 gene did not. 
Conclusion:  Real time PCR has proven useful for validating changes in recurrent 
GBMs that could have important clinical applications.      
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Introduction:                                                                                                                                  
 Tumors of the brain are one of the toughest types of cancers to study and 
treat. “Over 34,000 (1.5%) of the 
1.1 million cancers diagnosed 
annually in the United States are 
found to involve the brain. 
Approximately 17,000 of these are 
primary intracranial origin, with the 
remainder resulting from 
intracranial metastasis,” (Grossman 
and Loftus, 1999). “Approximately 
50% of all tumors occurring within 
the intracranial cavity fall under the 
heading ‘glioma.’ (Grossman and 
Loftus, 1999). Gliomas are defined as 
“a hetereogenous collection of 
neoplasms unified by the fact that they 
arise from glial tissues,” (Grossman and 
Loftus, 1999). Glioblastoma Multiforme 
(GBM) is the deadliest form of brain 
cancer. GBM is a type of astrocytic 
primary intracranial tumor that 
Figure 1: Coronal section anterior view revealing a GBM. Extracted 
from Grossman and Loftus, 1999. 
Figure 2: Giant Cell GBM showing enlarged neoplastic glial cells. 
Extracted from Grossman and Loftus, 1999. 
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accounts for 15-23% of cases. 35% of these cases are gliomas (Grossman and 
Loftus, 1999) (see Figure 1). As stated before, gliomas are tumors of glial origin 
(see Figure 2). Over 80% of gliomas are derived from astrocytic components of 
the glia. These tumors, termed astrocytomas, are the most common form of 
primary intracranial malignancy,” (Grossman and Loftus, 1999).Glial cells are 
non neuronal cells in the brain that are responsible for balance, destruction of 
pathogens, removal of dead neurons, and provision of  insulation and oxygen for 
other neurons. The World Health Organization (WHO) characterizes GBM as a 
grade IV astrocytic tumor (Louis et. al). It is the most common and aggressive 
brain tumor.  
  These intracranial tumors are the least differentiated and the most 
aggressive form of astrocytomas (Grossman and Loftus, 1999). Research has 
shown that the “intratumoral signal heterogeneity is apparent in the vast majority 
of cases and is thought to represent cystic, hemorrhage, and variability in cellular 
density,” (Grossman and Loftus, 1999).  Furthermore, GBMs are characterized by 
“the presence of an irregular rim of 
high signal intensity, which 
probably represents tumor mantle, 
where hemosiderin deposits, 
breakdown of the blood brain 
barrier (BBB), and a high nuclear to 
cytoplasmic ratio are present,” 
(Grossman and Loftus, 1999).  
Figure 3: Necrosis due to GBM Extracted from Grossman and Loftus, 
1999.  
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These rapidly dividing cells in the brain derived from glial cells characterized by 
a centrally located necrotic area, which is also extremely hypoxic (see Figure 3). 
The hypoxic area develops as the tumor outgrows its blood supply and spreads 
throughout the neighboring cells. The tumor tissue is hypercellular and if 
examined under a microscope, it would show high cellular density and mitotic 
activity of the rapidly dividing cells (Grossman and Loftus, 1999). The rapid 
division gives the tumor the ability to diffuse and infiltrate nearby areas resulting 
in inferior survival and short time to recurrence (Showalter et al., 2007). The 
necrotic center and the endothelial proliferation are characteristics commonly 
used to differentiate 
this tumor from 
another grade of 
astrocytoma 
(Grossman and 
Loftus, 1999). 
Research has also 
indicated that 
“necrosis is associated with significantly worse prognosis in anaplastic gliomas 
with both oligdendroglial and astrocytic components,” (Louis et al., 2007). The 
overall median survival rate is lower in patients with a necrotic center than the 
patients without (Louis et al., 2007).  
           Despite it being the most common type of brain cancer, there is no definite 
cure for GBM and research is ongoing but limited by the low life expectancy of 
Figure 4: Survival rate of patients with GBMs is poor. Extracted from Ohgaki 
and Kleihues, 2005). 
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the patients diagnosed with GBM (see Figure 4). Treatment of the tumor involves 
a combination of surgery, radiation, and chemotherapy. The patients are usually 
given more than one of these treatments at a time. Average survival after the 
primary GBM treatment is about 12 months (Loftus and Grossman, 1999).  “The 
most common cause of mortality among patients with glioblastoma, regardless of 
age, is recurrence at the primary tumor site,” (Loftus and Grossman, 1999). The 
average survival after diagnosis of recurrent tumor is only couple months 
maximum. Researchers and physicians currently recommend aggressive and 
postoperative radiation because improved survival rates have been correlated with 
aggressive resection (Grossman and Loftus, 1999). It is important to recognize, 
though, that combinations 
of treatment are highly 
dependent on the health 
status of the person. With 
age, the treatment available 
for the patient is minimal. 
Younger patients (usually 
less than 40) are able to 
withstand aggressive 
treatment but older patients are 
not (Ohgaki and Kleihues, 2005) 
(see Figure 5). Furthermore, the effectiveness of chemotherapy treatments in 
conjunction to radiation and total resection are reduced due to the heterogeneity of 
Figure 5: Age at diagnosis plays an important role in the life 
expectancy o f a GBMpatient. Table shows that the older the 
patient, the lower the life expectancy after diagnosis. Extracted 
from Ohgaki and Kleihues, 2005). 
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the GBM tumor cells. “As a result of this heterogeneity, each subpopulation of 
cells within a neoplasm may manifest variability in its sensitivity to treatments 
such as chemotherapy. Additionally, glioblastomas may be heterogeneous with 
respect to their physical structure, often containing differing microenvironments 
within the same tumor mass,” (Loftus and Grossman, 1999). Marginally viable 
but extremely resistant tumor cells can be spotted in the necrotic region of the 
GBM tumor which could have gotten past the drug penetration presented by 
radiation treatments or any other type of intervention, thus, lengthening the cell 
cycle, while using the hypoxia as a cover (Loftus and Grossman, 1999).  Current 
research focuses on what makes the primary vs. recurrent tumor so heterogeneous 
even though they have essentially originated from the same group of cells.  
There are two types of GBMs: Primary and Recurrent. Primary GBMs are 
tumors that stay in the region of the origin of the malignant mass (see Figure 6a 
& 7). Primary tumors are usually treated with a combination of surgery and 
radiation. Adjuvant chemotherapy treatment varies on the patient’s profile and 
health status.  
 
Figure 6a: Primary GBM tumor with a clear site of origin. 
Extracted from Loftus and Grossman, 1999).  
Figure 6b: Recurrent GBM tumor spreading out to 
different parts of the brain. Original site of tumor can 
still be seen.  
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As stated before, aggressive therapy of the primary tumor increases life 
expectancy to about 8-12 months. On the other hand, recurrent GBMs are tumors 
that have originated in the brain but then have 
metastasized to different parts of the brain and 
possibly other organs as well (see Figure 6b & 
8). This type of tumor is even harder to treat 
than the primary tumor because of its 
pathogenic characteristics. These tumors cells 
were able to resist primary aggressive therapy 
and have the ability to proliferate and invade at 
a higher rate than the primary tumor. Due to this 
reason, the life expectancy after the treatment or even diagnosis of the recurrent 
tumor is only about 2 months (at the most). There is a clear heterogeneous 
difference between the primary and the 
recurrent tumors, but there is not enough 
research to pinpoint the difference on a 
molecular level. Research indicates that there 
are certain genetic markers that differ from 
one grade to next grade of GBM. Certain 
genes end up being over or under expressed as 
needed for the cancerous cells to proliferate 
and spread throughout the brain (Ohgaki and 
Kleihues, 2005).  
Figure 7:Primary GBM with necrotic center. 
Figure 8: Metastatic primary tumor showing 
multiple foci. Extracted from Loftus and Grossman, 
1999). 
 Presentation of the tumor and patient profile is very different for GBMs 
compared to any other type of tumor. Presentation of the tumor in adults shows 
with severe, unbearable headaches due to the edema and pushing of the tumor 
against the cranial chamber,
brain’s ability to handle stressful situations or stress in general, weak focal vision. 
In adults, the tumor is mostly supra
hemisphere from the brain stem
Therefore, in adults the tumor is mostly in the cerebral hemisphere. Moreover, the 
tumor is mostly large in adults and presents in grade 
2, 3, 4 stage. On the other hand, in children, this 
tumor is usually grade 1and 
cerebellar signs, nausea, and vomiting (Loftus and 
Grossman, 1999).
           When a patient is presented with a case of 
GBM, if he/she is in decent health, then the tumor is 
resected. On average, MOST of the time there is 
recurrence (see Figure 9
person is healthy enough, the physician tries to 
that tumor as well. In either case, the goal is to buy time for the patient. In 
Table 1: Univariate analysis for the Effect of Genetic Alterations on Survi
Mean Age of GBM Patients. Extracted from Ohgaki an
 seizures, bleeding, decomposition, reduction of the 
-tentorial. The tentorium separates the cerebral 
 and cerebellum and supra means above. 
infra-tentorial tumor with 
 
). The second time, if the 
resect 
primary tumors, the 
person gets about a 
year, in 
Figure 9: Reccurent GBM
Notice that it is impossible to determine where 
the brain starts and the tumor ends.
val and 
d Kleihues, 2005).  
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 taking over the brain. 
 
8 
 
 
 
treatment, the person gets a few weeks. There is a lot of debate over the palliative 
treatment because if there is such a small time frame for survival, then why go 
through the aggressive treatment once or even twice? A GBM case is presented 
differently than any other form of cancer. Usually, a healthy patient is rushed into 
the hospital due to severe headache or any other symptom, diagnosed with brain 
tumor, taken to surgery usually at that visit, and then told that they only have 
about one year left. The time bought from the surgery is very much appreciated 
by the patients and it is also helpful for research purposes.   
Survival rate of GBM patients is 0.1%; therefore, any type of molecular 
change that can be determined could be helpful in the understanding of the 
heterogeneity of the different grades of GBM tumors. Previous research has 
shown genetic alternation association with GBM tumors. “… LOH 10q was the 
most frequent genetic alteration (69%), followed by EGFR amplification (34%), 
TP53 mutations (31%), p16INK4a deletion 
(31%), and PTEN mutations (24%),”(Ohgaki 
and Kleihues, 2005). Although, “studies on 
genetic alterations and how they influence 
response to therapy and survival are usually 
based on small number of patients, often 
contradictory and difficult to validate. In 
recent years, it has been established that 
primary glioblastomas and secondary 
glioblastomas derived from low-grade or Figure 10: Extracted from Ohgaki and Kleihues, 
2005. The image shows the age difference of 
primary and secondary GBM incidence (top). The 
image also describes specific gene changes 
occurance correlating age as a factor during 
incidence. 
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anaplastic gliomas develop though different genetic pathways,” (Ohgaki and 
Kleihues, 2005) (see Figure 10 & Table 1). The variation differs on many levels, 
including the age of the patient presenting the tumor. Nevertheless, poor 
prognosis cannot be defined by genetic alteration especially in older patients. 
Studies have shown that, “EGFR amplification, TP53 mutations, p16INK4a 
homozygous deletion, and PTEN mutations are considered key genetic events in 
the evolution of glioblastomas, but the presence or absence of any of these 
changes does not affect survival,” (Ohgaki and Kleihues, 2005)(see Figure 11 & 
12). “Although there may be as yet unidentified transformation-associated genes 
that are more frequently altered in glioblastomas of older patients and may affect 
the susceptibility to therapy, it is also possible that the sum of all changes, i.e. the 
level of genetic instability, is more relevant,” (Ohgaki and Kleihues, 2005). Other 
molecular research has indicated that hypermethylation of the MGMT promoter 
region could be associated with long term survival (long term GBM patients are 
patients who survive more than 36 months) (Krex et al., 2007).  The purpose of 
this research project focuses on the molecular differences of the primary vs. 
recurrent tumors. Why does a full resection for the recurrent tumors less effective 
in terms of life expectancy than primary tumor resection?  
 
 
 
 
Figure 11: Gene expressional changes according to age of the patient at the 
time of diagnosis. Extracted from Ohgaki and Kleihues, 2005). 
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Since both primary and recurrent tumors are essentially from the same group of 
cells, the research work focuses on looking at molecular changes in the evolution 
of cells, DNA copy number changes, and mRNA expression changes. Copy 
number changes are a marker of many diseases including cancer. Combining the 
genotype and copy number analyses gives greater insight into the underlying 
genetic alterations in cancer cells with identification of complex events including 
loss and reduplication of loci. This paper specifically looks at cancer related gene 
expression changes that showed consistent change in the microarray analysis in 
Figure 12: Known gene expressional changes according to grade of astrocytoma. Extracted from Ohgaki and 
Kleihues, 2005 
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the recurrent vs. primary tumors of DNA tissue from seven patients with both 
primary and recurrent GBMs at Upstate Medical University. A total of 18 
candidate genes (many with known roles in cancer proliferation) were selected for 
the study from the microarray results for validation: ANTXR1, CCND2, CLDN2, 
CSPG3, CSPG4, CSPG5, EDIL3, EGFR, ENPP2, GALNT6, NPTX2, PTPRZ1, 
SNCA, SNCAIP, ST18, STK17A, SYN2, and TPPP.  
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Methods: 
The Upstate Medical University tumor bank has tissues of seven patients 
with primary and recurrent GBMs. Three different approaches were used to 
determine the molecular changes. All three approaches were initiated with 
microarray GeneChip analysis method. Microarray GeneChip analysis uses 
probes and targets for different applications such as mutations and differences in 
expression on a chromosomal level (see Figure 13). Screening shows markers 
that are consistently changing, either increasing or decreasing. The assay 
mathematically averages out the noise and finds strong, consistent change. A 
downside of this method is that gene expression varies from person to person 
even in normal individuals. Therefore, the findings of the microarray analysis 
need to be validated to make sure that the expressional changes are due to the 
cancer and not just because normal biological genetic variation. As a result, all 
Figure 13: Microarray (GeneChip) analysis method 
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three approaches were validated with real time quantitative RT-PCR (Real Time 
qPCR). Real Time qPCR provides highly sensitive quantitative gene transcription 
measurements by amplifying and quantifying DNA simultaneously. Just like 
regular polymerase chain reactions, the DNA is denatured, annealed, and 
extended in Real Time qPCR method. Moreover, Real Time qPCR involves 
attachment of a SYBR green dye to generate signal values. SYBR green dye 
specifically binds to double-stranded DNA (dsDNA), but emits no signal when 
unbound (in the presence of single stranded DNA). The increase in SYBR green 
fluorescence is measured once during each PCR cycle, and the numbers of cycles 
it takes for this signal to surpass background is determined (as the delta Cp value). 
The real time qPCR studies that were performed were part of the 
validation for a multilevel analysis of recurrent GBMs that involved three 
complementary approaches. These three types of approaches are characterized on 
a convergent flow chart below. RNA expressional changes, DNA copy number 
changes, and the promoter methylation changes were focused upon in order to see 
which genes play an essential role that could help explain the recurrent vs. 
primary tumor changes and ultimately help identify new treatments for GBM (see 
Figure 14).  
Once the reactions were run for the three approaches, we asked two 
pertinent questions: a) Are there any common genes implicated from the 
approach? and b) Are these genes implicated in cancer? 
  
 
 
 
Microarray Methods
Genomic DNA and 
RNeasy kit for RNA and the Epicentre DNA purification kit for DNA). 
purity, and integrity of RNA and DNA were
and the Agilent Bioanalyzer
determined using the Affymetrix 
hybridization for over 47,000 fragments representing over 38,000 known genes.  
A single microarray (Human Genome Xba SNP Array) containing probes for 
~58,000 single nucleotide polymorphism
each tumor sample to probe for changes in DNA copy number, and chromosomal 
rearrangements. Lastly, b
DNA at CpG islands in the promoter sites of certain genes correlates with 
sensitivity of glioma cells to chemotherapeutics (including temozolamide, 
Everhard 2006), we 
status using a novel assay developed in the SUNY Microarray Core Facility that 
is analyzed with the Human Promoter 1.0 Arra
 
RNA were purified using standard protocols (Qiagen 
 confirmed by UV spectrophotometry 
 NanoChip. Changes in RNA expression were
U133 plus 2.0 Gene Chip which assays for 
s (SNPs) was also run on th
ecause previous studies have shown that
also mapped changes in genome-wide promoter methylation 
y (Affymetrix).  
Figure 14: 3-way GBM research method for this study
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Real Time RT-PCR Methods 
Quantitative real time RT-PCR (qRT-PCR) was performed to validate the 
changes seen by microarray screens. Briefly, 500ng of total RNA (in 12 µL PCR 
grade water) from each RNA preparation was used in an integrated reverse 
transcription (RT) first and second strand cDNA synthesis procedure that 
incorporates removal of genomic DNA contamination (QiantiTect, Qiagen, 
Valencia, CA). The RT reaction was terminated by heating to 95oC for 3 min, and 
diluted to a volume of 100µL for use in qRT-PCR. For quantification of transcript 
differences, 1.0 µL of the RT reaction from each of the samples was evaluated in 
duplicate PCR reactions for each gene of interest on 384-well plates in a Roche 
LightCycler 480 instrument (Roche, Indianapolis, IN).  
Each qRT-PCR reaction was performed in duplicate using the Roche 
SYBR Green Master Mix, in 10 µL volumes as follows: Activation at 95oC for 5 
min, followed by 40 cycles of 95oC for 10 sec, 58oC for 15 sec, and 72oC for 15 
sec.  Amplification in the absence of cDNA template was used to verify the 
absence of signal that would have occurred due to primer dimerization and 
extension or DNA contamination and end point melt-curve analysis was used to 
confirm the presence of single amplicons in each reaction well.   
Analyses of the data from the qRT–PCR studies was performed by first 
determining the number of PCR cycles that it took for each reaction to pass the 
detection threshold (Cp).  Then, to control for differences in starting material, 
these values were normalized for each gene from a specific sample by subtracting 
16 
 
 
 
the Cp value of 18S rRNA to generate a ∆Cp value.  Statistical significance of the 
PCR based differences in expression was determined using a 1-tailed pairwise 
Student’s T test. Pairwise relative differences in expression between the recurrent 
and primary tumors from the same subject were then determined by subtracting 
the ∆Cp value of each gene for the recurrent tumor from the ∆Cp value of the 
primary tumor.  These differences were termed ∆∆Cp values, and represent the 
Log2 difference in expression in recurrent versus primary GBMs.  For interpretive 
purposes, the Log2 differences can be converted to fold changes using the 
formula Fold Change = 2∆∆Cp.  In addition to examining the data for evidence of 
validating the overall change in expression seen by microarray, we also calculated 
the overall correlation in the pairwise differences observed between the recurrent 
and primary tumor using a Pearson’s R.  All of these values are displayed in the 
results that follow.  qPCR validation of the genes CLDN2, EDIL3, ENPP2, 
NPTX2, PTPRZ1, and STK17A was performed by Dr. Peter Kim. Validations of 
the remaining 12 genes were the focus of my research work: ANTXR1, CCND2, 
CSPG3, CSPG4, CSPG5, EGFR, GALNT6, SNCA, SNCAIP, ST18, SYN2, and 
TPPP.  
17 
 
 
 
Results:  
The results of this paper focus on the microarray expression analysis and 
their validation using real time qPCR.  On the microarray screen, some of the 
genes are repeated because there was more than one probe for that particular gene. 
T-test results show that most of the genes with expressional differences are 
statistically significant. The values that are not are the genes with more than one 
probe. Majority of the probes for that specific gene are still statistically 
significant. Expressional changes were averaged according to primary minus 
recurrent tumors from each of the seven patients on a log 2 scale. A negative 
value in the average log 2 column indicated a decrease in expression while a 
positive value indicates an increase in gene expression.   
Among the initial genes that were validated by Dr. Peter Kim, PTPRZ1 
and STK17A showed a decrease in expression while CLDN2, EDIL3, ENPP2, 
NPTX2, and SYN2 and showed an increase in expression in the recurrent tumor 
vs. primary tumor (see Table 2).   Round 2 candidate genes ANTXR1, CCND2, 
CSPG3, CSPG4, CSPG5, EGFR, and SNCAIP showed a decrease in expression 
whereas GALNT6, SNCA, ST18, SYN2, and TPPP showed an increase in 
expression in the recurrent tumor vs. primary tumor (see Table 3). 
Overall, there was a high correlation for the magnitude of expression 
changes seen for the 18 genes by both approaches (Pearson’s R = 0.852; P < 
0.001; see Figure 15).  Individually, 13 of the 18 genes showed statistically 
significant changes by PCR in the recurrent versus primary tumor pairs.  Of the 5 
18 
 
 
 
genes that did not validate at the P<0.05 level, 4 showed trends in the direction 
predicted by the microarray, while 1 gene did not.   
   
Table 2: Preliminary (round 1) microarray screen expressional changes and qPCR expressional changes. qPCR t – test 
analysis indicates whether the expressional changes from microarray screen were validated. 
Preliminary Validation (Fall 2007, performed by Dr. P. Kim)
Pairwise Pairwise
Gene T Test P Log2 Diff Pair 1 Pair 2 Pair 3 Pair 4 Pair 5 Pair 6 Pair 7
Claudin 0.000005 0.18 0.06 1.10 0.77 0.49 -0.64 0.12 -0.65
ENPP2 0.032863 1.99 0.37 0.00 1.44 0.49 5.88 3.47 2.25
EDIL3 0.054454 1.61 0.66 -0.05 1.17 0.76 4.45 2.77 1.50
NPTX2 0.076730 1.51 0.03 1.02 0.67 0.90 4.58 1.62 1.75
PTPRZ1 0.009154 -1.81 -2.06 -0.82 -4.80 -2.36 -1.40 -0.61 -0.62
STK17A 0.007560 -1.57 -2.41 -2.17 -2.89 -1.15 -1.11 -1.08 -0.21
Gene T Test P Log2 Diff Pair 1 Pair 2 Pair 3 Pair 4 Pair 5 Pair 6 Pair 7
Claudin 0.005773 2.61 1.63 1.33 2.76 2.05 6.37 3.60 0.55
ENPP2 0.005117 2.11 1.85 0.72 2.50 1.33 4.43 3.62 0.30
EDIL3 0.005230 2.70 1.03 1.01 2.98 1.79 6.64 3.34 2.13
NPTX2 0.005251 2.70 -0.25 2.97 3.61 2.91 5.98 2.54 1.15
PTPRZ1 0.008861 -1.88 -1.07 -0.15 -4.79 -1.86 -2.40 -0.61 -2.30
STK17A 0.021679 -1.03 -0.41 -0.88 -2.08 0.97 -1.67 -1.18 -1.98
Pairwise Log2 Differences by Microarray Screen
Pairwise Log2 Differences by PCR
19 
 
 
 
  
Round 2 Validation
Gene T Test P Log2 Diff Pair 1 Pair 2 Pair 3 Pair 4 Pair 5 Pair 6 Pair 7
ANTXR1 0.003806 -1.31 -2.00 -1.70 -2.28 -2.41 -0.54 -0.40 0.18
CCND2 0.022083 -1.01 -1.91 -0.64 -2.15 -0.89 -0.50 -0.80 -0.19
CSPG3 0.036635 -1.44 -2.00 -2.05 -2.12 -2.33 -1.24 0.04 -0.37
CSPG4 0.002523 -1.53 -3.10 -1.91 -2.34 -0.69 -0.46 -2.61 0.40
CSPG5 0.001982 -1.17 -1.87 -0.62 -2.82 -0.78 -0.81 -1.31 0.00
EGFR 0.037536 -0.86 -3.53 0.68 -0.63 -0.47 -1.22 -1.01 0.15
GALNT6 0.010349 1.69 2.82 1.42 1.24 3.14 2.17 1.72 -0.66
SNCA 0.001518 1.17 1.47 0.55 2.74 0.02 2.25 1.53 -0.35
SNCAIP 0.104891 -1.01 -1.56 -0.47 -2.94 -0.53 -0.48 -0.58 -0.47
ST18 0.004882 1.67 0.26 0.92 2.25 0.37 4.36 2.60 0.91
SYN2 0.000004 0.41 0.63 0.92 0.91 0.26 -0.22 0.51 -0.11
TPPP 0.018529 1.56 0.04 0.42 1.46 0.34 4.19 2.06 2.41
Gene T Test P Log2 Diff Pair 1 Pair 2 Pair 3 Pair 4 Pair 5 Pair 6 Pair 7
ANTXR1 0.063626 -1.30 0.11 -1.02 0.22 -1.05 -5.32 -2.05 -0.01
CCND2 0.021110 -1.97 -0.41 -0.20 -3.43 -0.64 -5.80 -2.03 -1.29
CSPG3 0.029636 -2.05 0.68 -0.87 -2.11 -3.79 -6.35 -0.98 -0.93
CSPG4 0.020126 -2.32 -0.85 -1.42 -1.79 -0.74 -6.94 -4.00 -0.51
CSPG5 0.018768 -2.15 -0.07 -1.30 -3.07 -1.62 -6.25 -2.67 -0.08
EGFR 0.122273 -0.98 -4.50 -1.87 -0.24 0.02 -0.90 -1.45 2.08
GALNT6 0.041500 0.98 3.54 0.93 0.88 1.04 0.79 -0.03 -0.31
SNCA 0.228274 0.47 1.76 -0.45 -1.55 1.01 0.14 -0.61 2.98
SNCAIP 0.032785 -3.27 -0.84 -2.17 -2.16 -10.76 -5.79 -2.02 0.81
ST18 0.237864 0.35 1.13 0.12 1.05 1.49 0.97 -0.38 -1.95
SYN2 0.468723 -0.03 0.10 -0.37 0.60 1.84 -0.20 -0.81 -1.39
TPPP 0.033173 2.04 -2.23 1.07 5.23 0.90 2.78 2.71 3.80
Pairwise Log2 Differences by Microarray Screen
Pairwise Log2 Differences by PCR
Table 3: Round 2 microarray screen expressional changes and qPCR expressional changes. qPCR t – test analysis indicates 
whether the expressional changes from microarray screen were validated.  
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Figure 15: Comparison of changes seen in recurrent versus primary GBM for 18 genes in initial microarray 
screen, and real time qPCR. Overall, there was a very high correlation in the difference seen for the two 
techniques (Pearson’s R = 0.852, P<0.001). 
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Conclusion: 
 The overall high correlation between the microarray expression analysis 
and the qPCR validation results indicates that Real time PCR has proven useful 
for validating changes in recurrent GBMs that could have important clinical 
applications. Of the round 2 gene validation, 7 out of 12 genes were statistically 
significant for expression change. The gene functions are presented in table 4.  
The biology of these seven genes can be related to tumor functions.  
 CCND2 is a cell cycle regulator (Lossos 2004). The average expression of 
CCND2 is decreased in the recurrent tumor compared to the primary tumor, thus, 
indicating that the high proliferation rate of the recurrent tumor may be the result 
of improper function of cell cycle regulator.  
 CSPG3 (also known as NCAN), CSPG4, and CSPG5 belong to the same 
family of genes. They are known to be responsible for the regulation of the 
extracellular matrix (Gladson 1999 & Zhang 2003). Real time validation showed 
that the average expressions in all three genes are decreased in the recurrent 
tumor. This shows that since the matrix is not regulated, the tumor cells can easily 
spread to the neighboring cells because there is not traffic in the extracellular 
matrix to slow down the proliferation of the tumor cells.  
 GALNT6 is known to be expressed in low levels in the brain. It is 
associated with fibronectin glycosylation kinetics. Furthermore, members of this 
family are responsible for the transfer of N-acetylgalactoamine to serine and 
threonine residues (a type of protein glycosylation) (Bennett 1999).The 
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expression of this gene in the recurrent tumor is shown to increase. Higher than 
normal levels of this gene in the brain could lead to increased glycosylation and 
mutations in the cell cycle, thus, promoting abnormal cell proliferation. 
 SNCAIP is a synuclein interacting protein (Chung 2001). The validation 
of this gene was chosen due to significant change of SNCA gene in the 
microarray analysis. We were not able to validate the SNCA expression change 
and therefore cannot make any conclusions about the SNCAIP expression change. 
 TPPP is known to promote aggregation of SNCA gene (Lindersson 2005). 
Even though expression of this gene is significantly increased in the recurrent 
tumor compared to the primary tumor, we cannot draw any conclusions about the 
role of this gene in tumor proliferation since the SNCA gene validation was not 
statistically significant. Nevertheless, the SNCA gene expression change from 
microarray analysis and real time PCR did show a trend in the same direction. 
SNCA has been known to play a role in neurodegenerative disorders; but more 
research needs to be conducted to analyze its correlation with TPPP gene and 
their role in proliferation of brain tumors.  
 Even though we were not able to validate the expressional change for 
ANTXR1 gene, it is worth mentioning that latest research has shown some 
correlation between ANTXR1 gene and other types of cancers. ANTXR1 has 
been known to be involved in vasculogenesis (Nanda 2004). Vasculogenesis 
involves the recruitment of blood supply for the tumor by forming new blood 
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vessels. If the blood supply growth can be shut down, then the tumor can be 
eliminated.  This could be useful for future therapeutic interventions.  
 This study shows that Microarray analysis and real time PCR can be used 
together to understand the gene expression change in GBMs. The findings can be 
used to improve upon and/or invent new treatment options for GBM patients 
which could, if not cure, increase the life expectancy of GBM patients.   
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Gene 
 
Function 
 
Reference 
ANTXR1 
 
vasculogenesis 
 
Nanda 2004 
CCND2   cell cycle regulator   Lossos 2004 
CLDN2 
 
Tight junction 
 
Thakur 2007 
CSPG 3    regulation of extracellular matrix   Zhang 2003 
CSPG4   regulation of extracellular matrix   Gladson 1999 
CSPG5   regulation of extracellular matrix   Gladson 1999 
EDIL3 
 
angiogenesis 
 
Aoka 2002 
EGFR 
 
cell signaling molecule 
 
Wang 2004 
ENPP2 
 
adherence, motility 
 
Kishi 2006 
GALNT6   galactosaminotranserase   Bennett 1999 
NPTX2 
 
neuronal development 
 
Carlson 2007 
PTPRZ1 
 
cell signaling  
 
Lu 2005 
SNCA 
 
neurodegenerative disorders 
 
Beyer 2008 
SNCAIP   SNCA interacting protein    Chung 2001 
ST18 
 
transcriptional regulation 
 
Steinbach 2006 
STK17A 
 
tumor suppressor 
 
Wittig 2002 
SYN2 
 
synaptogenesis 
 
Lee 2005 
TPPP   promotes aggregation of SNCA   Lindersson 2005 
Table 4: 18 gene functions with references that evaluate their relevance to cancer proliferation. The highlighted genes 
were validated by qPCR analysis. Red indicates a decrease in expression change and green indicates an increase in 
expression change in the recurrent GBM versus primary GBM 
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Summary: 
Molecular Analysis of the Genetic Heterogeneity 
Between Primary and Recurrent Glioblastoma 
 Glioblastoma multiforme (GBM) is one of the deadliest forms of brain 
cancer, and affects more than 18,000 new cases each year in the United States 
alone. Gliomas are defined as “a hetereogenous collection of neoplasms unified 
by the fact that they arise from glial tissues,” (Grossman and Loftus, 1999). Glial 
cells are non neuronal cells in the brain that are responsible for maintenance of 
homeostasis, destruction of pathogens, removal of dead neurons, and provision of  
insulation and oxygen for other neurons. There are two types of GBMs: Primary 
and Recurrent. Primary GBMs are when the tumor remains at the site of origin. 
On the other hand, in recurrent GBMs, the tumor has spread out to other parts of 
the brain from the site of origin. Presentation of the tumor and patient profile is 
very different for GBMs compared to any other type of tumor. Presentation of the 
tumor in adults shows with severe, unbearable headaches due to the edema and 
pushing of the tumor against the cranial chamber, seizures, bleeding, 
decomposition, reduction of the brain’s ability to handle stressful situations or 
stress in general, weak focal vision (Loftus and Grossman, 1999).  
 The current standard of treatment for GBM includes surgical removal of 
the tumor, along with radiation and chemotherapy.  Despite these treatments, 
recurrence of GBM is extremely common, and once it recurs, the life expectancy 
is measured in weeks or months.  The treatment plan for recurrent tumor is the 
same as the primary tumor depending on the health status of the patient. GBMs 
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are more common in older age individuals; therefore, the patient’s health status is 
usually not strong enough to handle another surgical operation with radiation and 
chemotherapy treatments. There is a lot of debate over the palliative treatment 
because if there is such a small time frame for survival, then why go through the 
aggressive treatment once or even twice? A GBM case is presented differently 
than any other form of cancer. Usually, a healthy patient is rushed into the 
hospital due to severe headache or any other symptom, diagnosed with brain 
tumor, taken to surgery usually at that visit, and then told that they only have 
about one year left. The time bought from the surgery is very much appreciated 
by the patients and it is also helpful for research purposes.   
  One of the reasons for the deadly nature of the recurrent GBM is thought 
to be selection for therapy-resistant tumor cells. Research indicates that there are 
certain genetic markers that differ from one grade to next grade of GBM. Certain 
genes end up being over or under expressed as needed for the cancerous cells to 
proliferate and spread throughout the brain (Ohgaki and Kleihues, 2005). In this 
project, we specifically looked at cancer related gene expression changes that 
showed consistent change in the microarray analysis in the recurrent vs. primary 
tumors of DNA tissue from seven patients with both primary and recurrent GBMs 
at Upstate Medical University. A total of 18 candidate genes (many with known 
roles in cancer proliferation) were selected for the study from the microarray 
results for validation: ANTXR1, CCND2, CLDN2, CSPG3, CSPG4, CSPG5, 
EDIL3, EGFR, ENPP2, GALNT6, NPTX2, PTPRZ1, SNCA, SNCAIP, ST18, 
STK17A, SYN2, and TPPP.  
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Whole-genome DNA microarrays were used to identify genes changed in 
mRNA expression in seven recurrent GBM samples compared to seven primary 
GBM samples from the same subjects.  Microarray GeneChip analysis uses 
probes and targets for different applications such as mutations and differences in 
expression on a chromosomal level. Screening shows markers that are 
consistently changing, either increasing or decreasing. The assay mathematically 
averages out the noise and finds strong, consistent change. A downside of this 
method is that gene expression varies from person to person even in normal 
individuals. Therefore, the findings of the Microarray analysis need to be 
validated to make sure that the expressional changes are due to the cancer and not 
just because normal biological genetic variation. As a result, Real-time 
quantitative RT-PCR was used in an attempt to validate changes seen by 
microarray for 18 genes of interest chosen from the microarray screen. Real Time 
qPCR provides highly sensitive quantitative gene transcription measurements by 
amplifying and quantifying DNA simultaneously. Once the reactions were run, 
we asked two pertinent questions: a) Are there any common genes implicated 
from the approach? and b) Are these genes implicated in cancer? 
The microarray experiments identified several dozen mRNA transcripts 
with evidence of significant differences in expression.  From these genes, we 
chose 18 for PCR validation.  The results of this paper focus on the microarray 
expression analysis and their validation using real time qPCR.  On the microarray 
screen, some of the genes are repeated because there was more than one probe for 
that particular gene. T-test results show that most of the genes with expressional 
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differences are statistically significant. The values that are not are the genes with 
more than one probe. Majority of the probes for that specific gene are still 
statistically significant. Expressional changes were averaged according to primary 
minus recurrent tumors from each of the seven patients on a log 2 scale. A 
negative value in the average log 2 column indicated a decrease in expression 
while a positive value indicates an increase in gene expression.  Overall, the PCR 
experiments validated the microarray findings quite well.  There was a very high 
correlation for the magnitude of expression changes seen for the 18 genes 
(Pearson’s R = 0.852, P < 0.001).  Individually, 13 of the 18 genes showed 
statistically significant changes by PCR in the recurrent versus primary tumor 
pairs.  Of the 5 genes that did not validate at the P<0.05 level, 4 showed trends in 
the direction predicted by the microarray, while 1 gene did not. 
 The overall high correlation between the microarray expression analysis 
and the qPCR validation results indicates that Real time PCR has proven useful 
for validating changes in recurrent GBMs that could have important clinical 
applications. Of the round 2 gene validation, 7 out of 12 genes were statistically 
significant for expression change. The biology of these seven genes can be related 
to tumor functions.  
 CCND2 is a cell cycle regulator (Lossos 2004). The average expression of 
CCND2 is decreased in the recurrent tumor compared to the primary 
tumor, thus, indicating that the high proliferation rate of the recurrent 
tumor may be the result of improper function of cell cycle regulator.  
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 CSPG3 (also known as NCAN), CSPG4, and CSPG5 belong to the same 
family of genes. They are known to be responsible for the regulation of the 
extracellular matrix (Gladson 1999 & Zhang 2003). Real time validation 
showed that the average expressions in all three genes are decreased in the 
recurrent tumor. This shows that since the matrix is not regulated, the 
tumor cells can easily spread to the neighboring cells because there is not 
traffic in the extracellular matrix to slow down the proliferation of the 
tumor cells.  
 GALNT6 is known to be expressed in low levels in the brain. It is 
associated with fibronectin glycosylation kinetics. Furthermore, members 
of this family are responsible for the transfer of N-acetylgalactoamine to 
serine and threonine residues ( a type of protein glycosylation) (Bennett 
1999).The expression of this gene in the recurrent tumor is shown to 
increase. Higher than normal levels of this gene in the brain could lead to 
increased glycosylation and mutations in the cell cycle, thus, promoting 
abnormal cell proliferation. 
 SNCAIP is a synuclein interacting protein (Chung 2001). The validation 
of this gene was chosen due to significant change of SNCA gene in the 
microarray analysis. We were not able to validate the SNCA expression 
change and therefore cannot make any conclusions about the SNCAIP 
expression change. 
 TPPP is known to promote aggregation of SNCA gene (Lindersson 2005). 
Even though expression of this gene is significantly increased in the 
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recurrent tumor compared to the primary tumor, we cannot draw any 
conclusions about the role of this gene in tumor proliferation since the 
SNCA gene validation was not statistically significant. Nevertheless, the 
SNCA gene expression change from microarray analysis and real time 
PCR did show a trend in the same direction. SNCA has been known to 
play a role in neurodegenerative disorders; but more research needs to be 
conducted to analyze its correlation with TPPP gene and their role in 
proliferation of brain tumors.  
 Even though we were not able to validate the expressional change for 
ANTXR1 gene, it is worth mentioning that latest research has shown some 
correlation between ANTXR1 gene and other types of cancers. ANTXR1 
has been known to be involved in vasculogenesis (Nanda 2004). 
Vasculogenesis involves the recruitment of blood supply for the tumor by 
forming new blood vessels. If the blood supply growth can be shut down, 
then the tumor can be eliminated.  This could be useful for future 
therapeutic interventions.  
 This study shows that Microarray analysis and real time PCR can be used 
together to understand the gene expression change in GBMs. The findings can be 
used to improve upon and/or invent new treatment options for GBM patients 
which could, if not cure, increase the life expectancy of GBM patients.   
 
 
